The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36834949

Authors

Anna Paola Capra

Alessio Ardizzone

Giuseppe Panto

Irene Paterniti

Michela Campolo

Lelio Crupi

Raffaele Squeri

Emanuela Esposito

Affiliations

Soon will be listed here.

Abstract

Over the last three years, humanity has been facing one of the most serious health emergencies due to the global spread of Coronavirus disease (COVID-19). In this scenario, the research of reliable biomarkers of mortality from COVID-19 represents a primary objective. Pentraxin 3 (PTX3), a highly conserved protein of innate immunity, seems to be associated with a worse outcome of the disease. Based on the above, this systematic review and meta-analysis evaluated the prognostic potential of PTX3 in COVID-19 disease. We included 12 clinical studies evaluating PTX3 in COVID-19 patients. From our research, we found increased PTX3 levels compared to healthy subjects, and notably, PTX3 was even more augmented in severe COVID-19 rather than non-severe cases. Moreover, we performed a meta-analysis to establish if there were differences between ICU and non-ICU COVID-19 patients in PTX3-related death. We combined 5 studies for a total of 543 ICU vs. 515 non-ICU patients. We found high significative PTX3-related death in ICU COVID-19 hospitalized individuals (184 out of 543) compared to non-ICU (37 out of 515), with an overall effect OR: 11.30 [2.00, 63.73]; = 0.006. In conclusion, we probed PTX3 as a reliable marker of poor outcomes after COVID-19 infection as well as a predictor of hospitalized patients' stratification.

Citing Articles

Prognostic Value of Pentraxin3 Protein Expression in Human Malignancies: A Systematic Review and Meta-Analysis.

Jung H, Kang J, Han K, Kim H Cancers (Basel). 2024; 16(22).

PMID: 39594709 PMC: 11593206. DOI: 10.3390/cancers16223754.

Disease progression associated cytokines in COVID-19 patients with deteriorating and recovering health conditions.

Han E, Youn S, Kwon K, Kim S, Jo H, Jung I Sci Rep. 2024; 14(1):24712.

PMID: 39433797 PMC: 11494080. DOI: 10.1038/s41598-024-75924-x.

Immune Dysregulation in the Oral Cavity during Early SARS-CoV-2 Infection.

Graves C, Babikow E, Ghaltakhchyan N, Ngo T, Liu C, Wang S J Dent Res. 2024; 103(12):1258-1270.

PMID: 39394771 PMC: 11562286. DOI: 10.1177/00220345241271943.

Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population.

Kumar S, Zoodsma M, Nguyen N, Pedroso R, Trittel S, Riese P Sci Adv. 2024; 10(39):eadq7006.

PMID: 39331702 PMC: 11430404. DOI: 10.1126/sciadv.adq7006.

Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus.

Delliere S, Chauvin C, Wong S, Gressler M, Possetti V, Parente R Nat Commun. 2024; 15(1):6966.

PMID: 39138196 PMC: 11322389. DOI: 10.1038/s41467-024-51047-9.

References

Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M . Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection. Front Immunol. 2022; 13:886431. PMC: 9226563. DOI: 10.3389/fimmu.2022.886431. View

Kukla M, Menzyk T, Dembinski M, Winiarski M, Garlicki A, Bociaga-Jasik M . Fetuin-A Deficiency but Not Pentraxin 3, FGF-21, or Irisin, Predisposes to More Serious COVID-19 Course. Biomolecules. 2021; 11(10). PMC: 8533535. DOI: 10.3390/biom11101422. View

Jenny N, Arnold A, Kuller L, Tracy R, Psaty B . Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29(4):594-9. PMC: 2661204. DOI: 10.1161/ATVBAHA.108.178947. View

Brunetta E, Folci M, Bottazzi B, De Santis M, Gritti G, Protti A . Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2020; 22(1):19-24. DOI: 10.1038/s41590-020-00832-x. View

Hu B, Huang S, Yin L . The cytokine storm and COVID-19. J Med Virol. 2020; 93(1):250-256. PMC: 7361342. DOI: 10.1002/jmv.26232. View

Moulana Z, Bagherzadeh M, Mirzakhani M, Rostami A, Mohammadnia-Afrouzi M, Shahbazi M . Increased Levels of serum Pentraxin 3 in Critical Coronavirus Disease-2019 Patients. Environ Sci Pollut Res Int. 2021; 29(57):85569-85573. PMC: 8248285. DOI: 10.1007/s11356-021-15183-9. View

Rothan H, Byrareddy S . The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109:102433. PMC: 7127067. DOI: 10.1016/j.jaut.2020.102433. View

Caironi P, Masson S, Mauri T, Bottazzi B, Leone R, Magnoli M . Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. Eur J Clin Invest. 2016; 47(1):73-83. PMC: 5414835. DOI: 10.1111/eci.12704. View

Assandri R, Accordino S, Canetta C, Buscarini E, Scartabellati A, Tolassi C . Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives. Biochem Med (Zagreb). 2022; 32(2):020901. PMC: 8996318. DOI: 10.11613/BM.2022.020901. View

10.

Genc A, Yaylaci S, Dheir H, Genc A, Issever K, Cekic D . The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia. Turk J Med Sci. 2020; 51(2):448-453. PMC: 8219078. DOI: 10.3906/sag-2011-32. View

11.

Capra A, Ardizzone A, Briuglia S, La Rosa M, Mondello S, Campolo M . A Systematic Review and Meta-Analysis of the Association between the FV H1299R Variant and the Risk of Recurrent Pregnancy Loss. Biology (Basel). 2022; 11(11). PMC: 9687207. DOI: 10.3390/biology11111608. View

12.

Margiana R, Sharma S, Khan B, Alameri A, Catalan Opulencia M, Hammid A . RETRACTED: The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study. Pathol Res Pract. 2022; 238:154128. PMC: 9476367. DOI: 10.1016/j.prp.2022.154128. View

13.

Raveendran A, Jayadevan R, Sashidharan S . Long COVID: An overview. Diabetes Metab Syndr. 2021; 15(3):869-875. PMC: 8056514. DOI: 10.1016/j.dsx.2021.04.007. View

14.

Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A . PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol Rev. 2018; 98(2):623-639. PMC: 5985957. DOI: 10.1152/physrev.00016.2017. View

15.

Ardizzone A, Capra A, Mondello S, Briuglia S, La Rosa M, Campolo M . H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. Genes (Basel). 2022; 13(6). PMC: 9222435. DOI: 10.3390/genes13061019. View

16.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

17.

Hansen C, Sandholdt H, Engel Moller M, Perez-Alos L, Pedersen L, Bastrup Israelsen S . Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3. J Innate Immun. 2022; 14(5):493-501. PMC: 9059012. DOI: 10.1159/000521612. View

18.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

19.

Ramirez G, Rovere-Querini P, Blasi M, Sartorelli S, Di Chio M, Baldini M . PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Front Immunol. 2019; 10:1135. PMC: 6548810. DOI: 10.3389/fimmu.2019.01135. View

20.

Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C . Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022; 54(1):1473-1487. PMC: 9132392. DOI: 10.1080/07853890.2022.2076901. View